Education
About Us
Working with TipRanks
Follow Us
Avita Medical (RCEL)
NASDAQ:RCEL
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.25Last Year’s EPS
-0.6Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -31.73%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in revenue, market expansion, and successful product launches, bolstered by operational efficiencies. However, challenges include a decrease in gross margin, higher-than-expected cash usage, and a pause in the vitiligo initiative. Overall, the positive aspects appear to outweigh the negatives.Company Guidance
During the AVITA Medical First Quarter 2025 Earnings Conference Call, significant guidance was provided on the company's strategic initiatives and financial outlook. CEO Jim Corbett highlighted a seven-fold increase in the U.S. addressable market, now estimated at over $3.5 billion annually, following the expansion into therapeutic acute wound care. The company's revenue for the first quarter increased by 67% year-over-year, driven by the deployment of RECELL GO and its expansion into trauma centers. AVITA launched RECELL GO mini, targeting smaller wounds in trauma settings, and Cohealyx, a collagen-based dermal matrix, both of which are expected to contribute significantly to revenue growth. CFO David O'Toole reiterated the full-year 2025 commercial revenue guidance of $100 million to $106 million, representing a 55% to 65% growth compared to 2024. Operating expenses are expected to decrease by approximately $2.5 million per quarter, aiming for GAAP profitability by Q4 2025. Despite a reported net loss of $13.9 million for the first quarter, the company remains confident in achieving its financial targets, bolstered by strategic sales force reorganization and increased adoption of new product offerings.Revenue Increase
Revenue for the first quarter increased 67% over the first quarter of the prior year, indicating strong traction and growth potential.
Market Expansion
The US addressable market expanded from $500 million to more than $3.5 billion annually, a seven-fold increase that reshapes the company's long-term growth trajectory.
Product Launches
RECELL GO mini and Cohealyx were launched, targeting trauma centers and expanding product offerings. The feedback has been positive, with adoption already underway.
Operational Efficiency
Reconfiguration of the sales model and operational efficiencies are expected to save $2.5 million per quarter in operating expenses.
Improved Net Loss
Net loss for the first quarter improved to $13.9 million from $18.7 million in the same period in 2024.
---
RCEL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RCEL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $9.33 | $6.97 | -25.29% |
Feb 13, 2025 | $8.78 | $10.57 | +20.39% |
Nov 07, 2024 | $12.40 | $11.95 | -3.63% |
Aug 08, 2024 | $7.93 | $9.57 | +20.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Avita Medical (RCEL) report earnings?
Avita Medical (RCEL) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Avita Medical (RCEL) earnings time?
Avita Medical (RCEL) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RCEL EPS forecast?
RCEL EPS forecast for the fiscal quarter 2025 (Q2) is -0.25.
---